RESEARCH MONOGRAPH · KDC-MN-249

Tandospirone

May 9, 2026 Kodiac biolabs Research Revised May 11, 2026 2 min read

Our opinion on this compound

64/100

The azapirone the West never adopted and thats made the literature one-sided in interesting ways

Tandospirone is the Asian-market 5-HT1A partial agonist anxiolytic that essentially took the buspirone scaffold, cleaned up the pharmacology, and got marketed in Japan and China while remaining basically unavailable in the West. The mechanism is selective 5-HT1A partial agonism with cleaner selectivity than buspirone (less D2 affinity, less alpha-1 affinity) and arguably a better tolerability profile.

The clinical literature is mostly Japanese and Chinese, with reasonable efficacy data in generalized anxiety disorder, mixed anxiety-depression, and an interesting and growing literature in cognitive enhancement contexts where the 5-HT1A partial agonism is hypothesized to facilitate cortical neurotransmission. The cognitive-effects literature is the most interesting and the most underexplored from a Western pharmacology standpoint.

What we find genuinely interesting is that tandospirone is essentially buspirone with the off-target pharmacology cleaned up, and the Asian literature on it has explored applications (cognitive enhancement, post-stroke recovery, neuroprotection in animal models) that the buspirone literature largely missed. Whether thats because tandospirone genuinely behaves differently or because the research traditions happened to develop differently is hard to say without more head-to-head work.

For research tandospirone is a useful clean 5-HT1A partial agonist tool, particularly if you want to study 5-HT1A contributions to cognition without the alpha-2 antagonist metabolite confound that 1-PP introduces in buspirone preparations. The cleaner selectivity makes interpretation easier.

The pharmacokinetics involve CYP3A4 metabolism with shorter half-life than ideal, similar to buspirone. Active metabolites contribute somewhat to overall pharmacological exposure.

What we dont know enough about is whether the Asian clinical literature would replicate in modern Western trial designs. Some of it would, some of it probably wouldn't, and the gap between research traditions makes it hard to evaluate without doing the experiments yourself.

Sourcing is the practical issue. Tandospirone is harder to find in the West than buspirone and vendor selection is thinner. Reference material is available from a smaller pool of suppliers. HPLC validation is doable on clean material.

Slept-on 5-HT1A tool, particularly for cognitive research applications. The literature gap is real and worth closing.

Evidence: 60
Mechanism: 80
Reliability: 65
Safety: 80
Sourcing: 55
Value: 55
Signal: 60
Staying power: 55

Plain-language summary Intrigue 47 / 100

Tandospirone (Sediel, Senparen) is a Japanese-developed second-generation azapirone from Sumitomo, approved in Japan in 1996 and China in 2004. It has not been pursued in Western markets. Mechanistically it is closely related to buspirone, partially activating the serotonin 5-HT1A receptor, but with somewhat higher intrinsic activity at the receptor (around 60 percent versus buspirone's 35 percent). Used for generalized anxiety and adjustment disorders, with some research interest in cognitive effects through 5-HT1A in the prefrontal cortex. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

5-HT1A partial agonist anxiolytic (Asian markets)

A second-generation azapirone 5-HT1A partial agonist marketed in Japan and China; not approved in Western markets.

Abstract

Tandospirone ((1R,2R,6S,7S)-4-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]butyl})-4-azatricyclo[5.2.1.02,6]decane-3,5-dione; CAS 87760-53-0; molecular formula C21H29N5O2; molecular weight 383.49) is a second-generation azapirone 5-HT1A partial agonist developed at Sumitomo and approved in Japan in 1996 (Sediel) and China in 2004 (Senparen). Receptor profile is closely related to buspirone: 5-HT1A affinity approximately 27 nM (intrinsic activity approximately 60 percent, higher than buspirone); minimal D2 affinity. Compared to buspirone, the higher 5-HT1A intrinsic activity is hypothesized to produce somewhat greater anxiolytic and antidepressant effect. Plasma half-life is approximately 1 hour; metabolism is via CYP3A4 with active metabolite 1-PP common to the azapirone class. Approved indications include generalized anxiety disorder and adjustment disorder with anxiety; off-label use in depression. Not approved in the US or EU. Used as a reference azapirone with higher 5-HT1A intrinsic activity than buspirone in mechanism studies.

Mechanism of action

5-HT1A partial agonist (higher intrinsic activity than buspirone, ~60 percent). Same azapirone class with shared 1-PP active metabolite.

Reported research dose ranges

Clinical 30 to 60 mg per oral administration daily, in divided doses. Rodent studies 1 to 30 mg/kg/day.

References

Shimizu H, et al. Pharmacological properties of tandospirone, an anxiolytic agent. Folia Pharmacol Jpn 1995.
Tanaka H, et al. Tandospirone, a novel 5-HT1A partial agonist. Neuropharmacology 1995.
Nishitsuji K, et al. Tandospirone: clinical experience in Japan. CNS Drug Rev 2004.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-249 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Tandospirone

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs